FDA approves first drug in new class of antibiotics
The Lancet 2000; 29 April, 355: 1523.
One of the problems of drug resistant bacterial infections is MRSA (Methicillin Resistant Staphylococcus Aureus) which has become a most dangerous infection. This bacteria has now become Vancomycin-resistant.
A new class of antibiotic has now been approved. The antibiotic named Zyvox (Linezolid) has novel mode of action, it blocks bacterial protein production by disrupting the binding of bacterial ribosome. It is hoped that this will make the treatment of MRSA infection simpler.